Pfizer Global Medical Grants and Rethink Announce a Quality Improvement Initiative in Metastatic Breast Cancer

Governance and Public Policy
Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Tuesday 5th, April 2022

External Deadline: Friday 8th, April 2022


Request for Proposals (RFP)

Improving the Care of Patients Living with Metastatic Breast Cancer

Rethink Breast Cancer (Rethink) is known for making positive change and rethinking the status quo when it comes to breast cancer. Rethink educates, empowers and advocates for system changes to improve the experience and outcomes of those with breast cancer, focusing on historically underserved groups: people diagnosed at a younger age, those with metastatic breast cancer and people systemically marginalized due to race, income or other factors. Through collaboration, Rethink keeps the community’s voice firmly at the centre and drives impact in ways that matter most.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Date RFP Issued: January 27, 2022

Geographic Scope: Canada

Clinical Area: Oncology – metastatic breast cancer

Link to full RFP: Improving the Care of Patients Living with Metastatic Breast Cancer

Application Due Date: April 8, 2022; 11:59 pm EST

Specific Area of Interest: The intent of this RFP is to encourage proposals for the implementation of strategies that will measurably improve the quality of care of metastatic breast cancer (mBC) patients. Projects should use optimal measures to improve care for patients with mBC, where treatment goals focus on improving quality and length of life as there is, to date, no known cure. In addition, preference will be given to projects that propose to address disparities in the management of mBC in underserved patient populations.


Topics of highlighted interest include, but are not limited to:

  • Multi-disciplinary care models (e.g., nurse navigator, palliative care, psychological/mental health support)
  • Address disparities in mBC related care for those marginalized due to age, race, income or other factors (equity, diversity, inclusion, accessibility)
  • Use Real World Evidence (RWE) to improve quality of care for mBC
  • Strategies to encourage shared-decision making between patients and their healthcare teams
  • Improved access to precision medicine and/or alternative diagnostic tools (e.g. liquid biopsy), especially considering the current COVID-19 pandemic
  • Approaches to optimize care throughout the patient cancer experience, including optimal access to clinical trials and evidence-based treatment

All submissions must include an overall “lay person’s” summary of the project proposal (please limit project summary to 5 sentences or less).

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: January 28, 2022